Replies to post #132022 on Avid Bioservices Inc (CDMO)

[volgoat]

also mentioned on page 22.

[biopharm]

Remember DTRA 2013 report page 15 mentioning Peregrine

"ultiple Target Products

Broad Spectrum (virus)

Phase 2 clinical trials—Bavituximab:

Developed by Peregrine Pharmaceuticals, Inc.

Virus-induced activation and apoptosis result in a loss of lipid asymmetry, with phosphatidylserine appearing on the outer, exposed leaflet.

Removes enveloped viruses from the bloodstream, induces ADCC to eliminate virally infected cells. "

Dr Steve Younger was head of DTRA and now he just landed at Sandia National Laboratories....on May 1, 2017

http://carnegieendowment.org/2001/08/10/dr.-stephen-younger-to-head-defense-threat-reduction-agency-pub-10258